Scott C. Brun

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Sarah Palmer, Frank Maldarelli, Ann Wiegand et al. · Proceedings of the National Academy of Sciences · 2008 · 646 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +14

ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

Frank Maldarelli, Sarah Palmer, Martin King et al. · PLoS Pathogens · 2007 · 334 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Dale J. Kempf, Jeffrey D. Isaacson, Martin King et al. · Journal of Virology · 2001 · 233 citations

Life Sciences, Genetics, Infectious Diseases +17

Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients

Constance A. Benson, Steven G. Deeks, Scott C. Brun et al. · The Journal of Infectious Diseases · 2002 · 154 citations

Medicine, Pharmacology, Pharmacotherapy +17

The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

Cheri E. Klein, Yi‐Lin Chiu, Walid M. Awni et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 153 citations

Pharmacy, Pharmacokinetics, Pharmacology +17